Lipocine adds to PPD setbacks as Tepezza scores, batoclimab misses in TED

This week’s clinical updates include another setback for a rapid-onset oral postpartum depression candidate, alongside divergent Phase III readouts for thyroid eye disease therapies, with a win by Amgen and a miss by Immunovant.

Shares of  Lipocine Inc. (NASDAQ:LPCN) fell 78% last Thursday, erasing about $75 million from its market cap, after the company’s oral brexanolone, LPCN 1154, failed to improve Hamilton Depression Rating Scale-17 scores versus placebo in individuals with postpartum depression...